Disitamab vedotin trials for Breast cancer

All Disitamab vedotin trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Disitamab vedotin for Breast cancer

• Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
  NCT05904964 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 3 locations
• Disitamab Vedotin (RC48-ADC) in Breast Cancer
  NCT05851677 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
  NCT06278870 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
  NCT06642545 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• RC48-ADC in HER2-low Advanced Breast Cancer
  NCT05831878 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 1 location

Common questions

How many trials study Disitamab vedotin for Breast cancer?

5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.